Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
A 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma. Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors, our patient was administered rapamycin for 6 months. During this time, the renal angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in size again after readministration of rapamycin.
Wienecke
Ralf
R
Department of Dermatology, Tuberous Sclerosis Center, Ludwig-Maximilian-University Munich, Gemany. ralf.wienecke@med.uni-muenchen.de
Fackler
Ingrid
I
Linsenmaier
Ulrich
U
Mayer
Karin
K
Licht
Thomas
T
Kretzler
Matthias
M
D000328:Adult; D018207:Angiomyolipoma / Q000188:drug therapy* / Q000209:etiology; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000150:complications*
D000903:Antibiotics, Antineoplastic; D020123:Sirolimus